SB's KYTRIL OVERCOMES UNFAVORABLE ADVISORY COMMITTEE REVIEW TO GET FDA APPROVAL AS FIRST-LINE CHEMO ADJUNCT; NOW IT FACES ENTRENCHED ZOFRAN IN MARKETPLACE
Executive Summary
SmithKline Beecham's Kytril (granisetron) will enter the cancer anti-emetic market against an entrenched Glaxo product, Zofran (ondansetron) with two significant challenges: (1) the fallout from a skeptical advisory committee review of the product in mid-March; and (2) a probable declining price range in the category.